Search Results

Zhuang, Y., et al., Structural insights into the human D1 and D2 dopamine receptor signaling complexes Hu, Y., et al., Identification of a five-gene signature of the RGS gene family with prognostic value

Adapted from: Zhang Y, Tang H, Chen W, Zhang J.

in a wide range of inflammatory, autoimmune and infectious diseases (Proudfoot 2002), and in recent years immunosuppressive tumor microenvironment, and facilitate metastatic spread (Nagarsheth, Wicha, and Zou

Hello Readers👋, We're excited to share our weekly newsletter with you. with the latest research and advancements in the field with our convenient, weekly news delivered to your You can always adjust your email preferences in your account settings. Below is your Classified GPCR News at a glance for January 9th to January 15th, 2023. and more Isolation and functional identification of secretin family G-protein coupled receptor from Y-organ

M., Pérez-Hernández, G., Batebi, H., Gao, Y., Eskici, G., Seven, A.

Shocking GPCR revelations await you. Donna Matzov ,  Dominic R Huxley ,   Peter Gmeiner ,  Peter J McCormick ,  Dorothee Weikert ,  Masha Y A single platform to connect from anywhere in the world  And if you go for a Premium Membership , you'll Thank you for your understanding and support! Get your 5-day free trial TODAY!

Allosteric Interactions When should you push the native system—and when should you partner with it? If your team is arguing about “potency vs. effect size vs. duration,” this is your playbook for aligning Your membership gives you:   📚 Proven frameworks for real-world discovery 🌍 Flexible, on-demand lessons you—in the best possible way—is the day you know you’re onto something. B y integrating them into GPCR workflows, discovery teams can accelerate identification, characterization

ligand binding, receptor activation, desensitization and trafficking is the apelin receptor (APJ) (Y.

If you'd like to showcase your work, please email us at Hello@DrGPCR.com. We look forward to seeing you in a few days at the Molecular Pharmacology GRC and the associated Molecular Yamina Berchiche, our founder. Below is your Classified GPCR News at a glance for May 29th to June 4th, 2023. Pharmacological inhibition of neuropeptide Y receptors Y1 and Y5 reduces hypoxic breast cancer migration

If you are curious about the material and methods or want more information, here is the published article W.; Högl, B.; Bainbridge, J.; Buchfuhrer, M.; Hadjigeorgiou, G.; Inoue, Y.; Manconi, M.; Oertel, W.; Springer Netherlands: Dordrecht, 2014; pp 55–74. https://doi.org/10.1007/978-94-007-7423-0_4 . (12)      Yung-Chi Structure-Based Design of High-Affinity Fluorescent Probes for the Neuropeptide Y Y1 Receptor. J.

We'll see you in Mexico City! Member Profile Antony Boucard Professor Centro de Investigación y de Estudios Avanzados del IPN (Cinvestav What is your backstory? Don’t be surprised if you find yourself singing Daddy Yankee’s “Gasolina” from the top of your lungs while executing your best perreo or Luis Enrique’s “Yo no sé mañana” while a stranger takes you floating

mutant-as-the-basis-for-personalized-high-throughput-drug-screening References Grimes, J., Koszegi, Z., Lanoiselée, Y.

Nature communications, 8(1), 443. https://doi.org/10.1038/s41467-017-00357-2 Jong, Y. Z., Wilderman, A., Katakia, T., McCann, T., Yokouchi, H., Zhang, L., Corriden, R., Liu, D., Feigin, M

6P4]CCL5), a chemokine antagonist ([5P7]CCL5), and a small-molecule inverse agonist (maraviroc) (Tan, Zhu there are four distinct pathways through which structural alterations in the binding site influence Y2446.44 hydrogen bonding to E2837.39 by A4 of CCL3; c) Route 3 - characterized by steric effects between TM2 and Y3 In ACKR3, the presence of a tyrosine at position 6.40 plays a role in its constitutive activity (Yen, Schafer et al. 2022) which is also supported by mutagenesis studies (Han, Tachado et al. 2012, Yen,

funding into small biotech companies developing novel technology platforms to target GPCRs in recent years Within the last two years, three investments stand out: · Tectonic Therapeutics: received $80 platform (summarized in Figure 2) can be used to complete a discovery campaign within only 6-12 months, yielding There is a great deal of scientific and business interest in solving this problem, and the last two years fully integrated PROcisionXᵀᴹ discovery platform Structure-based validation of Orion’s approach Zheng, Y.

Yet curiosity and chemistry pulled him into the world of GLP-1R, pancreatic β-cells, and the biological questions David Hodson had been exploring for years. If this behind-the-scenes story resonated, you’ll love the full conversation.

Where’s your dose justification?   How consistent is your manufacturing?   can align your strategy to de-risk not just your data, but your decisions . If you can’t see them too, you’re not building strategy, you’re building surprises. If you wait for the FDA to point out what’s missing, you’re already behind. Because by the time they do, your timelines will stretch, your budgets will strain, and your confidence

assays—particularly membrane-based radioligand binding—often provide high-throughput measurements, yet In this article, you’ll learn:   How live-cell HCS provides physiologically relevant affinity measurements

moment was a cold email from a biologist he’d never met, asking if he could synthesize a molecule “when you That simple ask pulled a young chemist out of the fume hood and into the messy, electrifying world of Over the years, they learned from each other in ways that shifted both careers. If this behind-the-scenes story resonated, you’ll love the full conversation. 🎧 Listen to the full episode

If your work touches GPCR pharmacology, these insights aren’t optional—they’re essential. When you see the distortions baked into the system, you interpret your data differently and protect your What You’ll Learn Why peptide–fluorophore probes succeed where antibodies fail How parallel synthesis Don’t Fall Behind—Access the Edge You Need Already a Premium Member? Help us reach more scientists by providing quick rating on Spotify or Apple Podcasts — and a YouTube

In this session, you’ll gain: How system sensitivity transforms potency, efficacy, and agonist classification Why Terry’s Corner Give You The GPCR Pharmacology Insights You Need Terry’s Corner gives discovery scientists those who invest in deeper GPCR pharmacology insights today will shape tomorrow’s breakthroughs. 40 years of expertise at your fingertips: Explore the full library ➤

For years, the GPCR community wrestled with unreliable antibodies. For years, the data made no sense. The signaling didn’t line up. You need genetics teams for variant interpretation, metabolic phenotyping facilities for in vivo work It’s about trust — the kind of trust built when collaborators confirm your data, replicate your results , and call out your blind spots before reviewers do.

Yet, despite remarkable progress, HCS workflows remain vulnerable to several performance-limiting factors In this blog, you’ll learn:  How HCS works and why it is increasingly central to GPCR-based drug discovery

Sometimes the things you think are going to end up on the cutting-room floor become the best work. This solved a long-standing problem in GPCR biology: You can't understand signaling if you can’t see  We’re not here long enough to spend 30 years collaborating with people we don’t enjoy. For Early-Career Scientists Don’t optimize your trajectory for papers. Optimize it for questions that won’t leave you alone. Scientific progress is rarely linear.

You always need a scientific anchor — but you also need the courage to follow data where it leads. For real translational understanding, you need to see  the receptor in context. They start with people you actually like working with . don’t make sense yet. Sometimes the experiments you almost quit are the ones that matter most.

Yet, any pharmacologist who’s pushed beyond textbook theory knows: biology rarely plays fair. In this session, you’ll gain: A clear conceptual map of Schild analysis and its origins. In the full lecture, you will learn how to extract affinity even in this dual-behavior scenario: Focus Calcium flux assays, though tricky, yield valid Schild plots when analysis excludes non-equilibrium maxima Modern pharmacology has powerful modeling software, yet Schild analysis remains the litmus test for mechanism

  ✅  You don’t need to abandon your scientific instincts. But you do need to adapt them if you want your startup to scale .     Unless you update the way you lead, your startup will struggle to translate insight into impact.   Leadership isn’t in your lab notebook; it’s in how you decide     How to Know If You're Still Leading If you find yourself looping decisions or delegating them upward, you might be leaning on scientific

When you walk into a typical academic lab, the boundaries are obvious: this PI’s corner, that group’s The structure you train in often matters more than the experiment you start with. Monash team built rotational PhD cohorts  — students cycled through multiple groups in their first year Mini Timeline: How the Model Evolved Year 0  — Shared lab space established; PI buy-in secured Year 2   — Core imaging and signaling platforms launched Year 4  — Pooled grants fund expansion and training

Instead of a dozen wells, you could test hundreds. For Early-Career Scientists: Don’t over-invest in proving your pipetting skills. Like many, it was a mix of opportunity, timing, and the courage to say yes before everything was figured Technical mastery opened doors, but what kept her moving was knowing when to say yes before everything Mini Timeline: Manual assay years — technical rigor as foundation Technology boom — scaling curiosity

Yet that summer research placement cracked open a new reality: the thrill of asking questions no one For Early-Career Scientists: Your pivotal moment might not feel like fireworks. It might be quiet, subtle—an idea you can’t stop thinking about. Pay attention to that. But luck only works if you say yes when the door opens. For young scientists, that summer moment is waiting.